Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Introduction of PCV-10 in Kenya reduced pneumococcal bacteria in HIV-positive adults, highlighting benefits of immunization

Two years after the introduction of 10-strain pneumococcal conjugate vaccine (PCV-10) in Kenya, the percent of HIV-positive adults who carried pneumococcal bacteria declined significantly (from 43% to 28%), but did not decline in HIV-negative adults. However, the reduction in carriage of pneumococcal strains that are in PCV10 declined significantly in both HIV-positive and HIV-negative adults. This reduction was still four times higher in HI- positive vs. HIV-negative adults (2.8% vs. 0.7%), indicating that HIV positive adults continue to be at considerably higher risk of invasive pneumococcal disease than HIV-uninfected adults.

Nasopharyngeal carriage is an indicator of the risk for invasive pneumococcal disease and pneumonia

Full Citation:
Kobayashi M, Bigogo G, Kim L et al.. 2020. Impact of 10-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage and antibiotic susceptibility patterns among children aged <5 years and adults with HIV infection, Kenya 2009-2013. Clinical Infectious Diseases. 70(5).

Title of Article: Impact of 10-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage and antibiotic susceptibility patterns among children aged <5 years and adults with HIV infection, Kenya 2009-2013

Author(s): Kobayashi M, Bigogo G, Kim L et al.

Publication Year: 2020

Publication Name: Clinical Infectious Diseases

Publication Volume: 70(5)

Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/30959526/

DOI (Digital Object Identifier): 10.1093/cid/ciz285

Topics: Health

Disease Vaccines: Pneumococcal disease/PCV/PPSV

Countries: Kenya

WHO Regions: Africa